News · 26 weeks125+86%
2026-04-122026-10-04
Mix4090d
- Other21(53%)
- Insider11(28%)
- Analyst3(8%)
- Earnings2(5%)
- SEC Filings2(5%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Karsanbhai Surendralal Lanca4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Coe Mary Ellen4 - Merck & Co., Inc. (0000310158) (Issuer)
- PRMerck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 29. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr
- PRCAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization ProgramKIRKLAND, QC, Sept. 28, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, welcomes Ontario's decision to include CAPVAXIVE® in its publicly funded adult immunization program. This addition helps expand access to pneumococcal immunization for eligible older adults in Ontario. CAPVAXIVE® is approved by Health Canada for adults 18+ to help prevent invasive pneumococcal disease (IPD)—including serious infections like sepsis, meningitis, and bacteremic pneumonia—caused by 21 Streptococcus pneumoniae serotypes.As pneumococcal disease trends continue to evolve, ongoing surveillance of IPD-causing S. pn
- PRMerck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) InhibitorMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. ("SciBrunch"), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor."Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth," said George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories. "This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhib
- PRIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily WithdrawnThe Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE:MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions with the U.S. Food and Drug Administration (FDA) that data supporting the application, including from the IDeate-Lung01 phase 2 trial, do not satisfy requirements needed to support an accelerated approval for the proposed indication.
- PRMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular EdemaRemigromig demonstrated non-inferiority to active control ranibizumab for mean change from baseline in best-corrected visual acuity (BCVA) at week 52 Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, which is involved in the repair and maintenance of the blood-retinal-barrie
- PRU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier in the treatment journey Newly published European Respiratory Society (ERS) clinical guidelines provide updated evidence-based recommendations for the treatment of PAH Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signali
- PRMerck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul TremblesKIRKLAND, QC, Sept. 21, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is proud to be the presenting partner of Chiharu Shiota: The Soul Trembles, a landmark contemporary art exhibition making its North American premiere at the Montreal Museum of Fine Arts (MMFA) from September 26, 2026, to February 14, 2027. Organized by the Montreal Museum of Fine Arts and the Mori Art Museum, Tokyo, this comprehensive retrospective represents over thirty years of Berlin-based Japanese artist Chiharu Shiota's creative evolution. The highly anticipated art exhibition features Shiota's signature site-speci
- PRMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in JapanKEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minute Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administered in one minute every three weeks or in two minutes every six weeks.
- PRMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVDebbie Allen, famed actress, director, producer and longtime HIV advocate, joins Merck to launch the initiative and honor the community Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today launched Your Hive of Whole Health, a multi-year educational program that helps people living with HIV build personalized networks of support to address their physical, mental, emotional, and social well-being. Unveiled at the 2026 U.S. Conference on HIV/AIDS (USCHA) in Anaheim, California, Sept. 17-20, 2026, the initiative aims to honor the strides made toward ending the epidemic while emphasizing that future progress depends on a collective focus on whole person health. "Thi
- PRPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid TumorsSEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE:MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. This combination will be evaluated under an amendment to the Company’s ongoing Phase 1/2a study of [212Pb]PSV359 in patients with certain t
- PRHistoric First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received U.S. Food and Drug Administration ("FDA") clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class
- PRMerck to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, 2026, at 3:20 p.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to
- PRMerck to Participate in the Wells Fargo 21st Annual Healthcare ConferenceMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Sept. 09, 2026, at 2:15 p.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-e
- INSIDERNew insider Gupta Gaurav K claimed ownership of 750 shares (SEC Form 3)3 - Merck & Co., Inc. (0000310158) (Issuer)
- ANALYSTMerck downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded Merck from Outperform to Sector Perform and set a new price target of $150.00
- ANALYSTMerck upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Merck from Equal-Weight to Overweight and set a new price target of $179.00
- PRMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaFirst and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor to train and activate the immune system to recognize and fight cancer Merck (NYSE:MRK), known as MSD outside of the United S
- INSIDEREVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- ANALYSTMerck upgraded by Daiwa Securities with a new price targetDaiwa Securities upgraded Merck from Neutral to Outperform and set a new price target of $143.00
- INSIDEREVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
MRK FAQ
7 questionsWhat does Merck & Company Inc. do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected...Where does MRK stock trade?
Merck & Company Inc. (MRK) is listed on NYSE.What sector and industry is MRK in?
Merck & Company Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does MRK pay a dividend?
MRK's most recent ex-dividend date was 2026-09-15 with a cash dividend of $0.85 per share. No future ex-date is on file yet.What are analysts saying about MRK?
Merck & Company Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform on 2026-08-20.What companies are similar to MRK?
Notable peers in the same industry include NVS (Novartis AG), AZN (AstraZeneca PLC), AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), PFE (Pfizer Inc.). Compare MRK side-by-side with any of them on Quantisnow.How can I track MRK on Quantisnow?
Quantisnow aggregates Merck & Company Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRK to receive live email and push alerts on every new disclosure.